Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By Notable Calls (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Expedia Inc (NASDAQ:EXPE): Barry Back To His Old Tricks

% of readers think this story is Fact. Add your two cents.


Expedia Inc (NASDAQ:EXPE) was up 3 pts (13%) yesterday in after hours trading after the online travel company announced its intention to break into two separate operating units: 1) core Expedia and 2) TripAdvisor.

While most of the analyst community sees the news as a mild positive for the stock, RBC Capital analyst Ross Sandler is out with an interesting trading call, telling clients to actually fade the rally:

- The rationale is simple, at $22.40 investors are paying 4.6x OIBDA for core Expedia if we were to assign a peer-average vertical content multiple to TripAdvisor (10x). We think Trip deserves the 10x, given its dominant position in the travel content space. Recent M+A multiples for quality niche content assets are ~12x forward OIBDA (INET, RATE, etc), which we don’t expect to realize immediately upon spin for Trip, and given the one-time Google Places organic traffic step-down, we believe 10x is warranted. For core Expedia, we think the correct multiple is ~6x OIBDA, which is likely a conservative estimate of what a potential acquirer would pay for a slow growth OTA asset, especially given recent eDreams, Go Voyages and Opodo transactions at 10x-12x OIBDA. While we could see shares drift higher in anticipation of the spin and a possible FY guidance raise this quarter to account for the AA deal, history would suggest that fading this rally may be the right call. EXPE remains Outperform rated and our $28 target is based on 15x EPS, 8x OIBDA and a 10% FCF Yield.

Obvious Spin Positives: Removing the conglomerate multiple discount is the value creation behind the spin. Additionally, Trip can now operate independently, and in theory, invest to re-accelerate growth. Assigning 10x 2011 OIBDA for Trip and 6x for core Expedia, with full cost allocation, generates a $25 target valuation; shares traded close to our fair value in post-market trading.

Potential Spin Negatives: While Trip can operate independently, core EXPE benefits greatly from Trip ownership with essentially zero cash-cost “barter” advertising on Trip that it will now have to pay for, or risk Trip allocating that inventory elsewhere (assuming there is demand). We could see selling pressure in either company post-spin from investors who want to only own one or neither, which we witnessed post the IACI break-up, including Liberty Media’s 18% stake. Lastly, we don’t know details of the capitalizations, but core EXPE is likely to assume the $1B net debt, which may limit its flexibility to improve the business, which happened to some of the debt-burdened IAC spinco’s.

IACI Spin Analysis: IAC’s one-to-five spin vastly underperformed the Nasdaq and S+P over a 3 month, 6 month, and to-date basis , as did EXPE post its initial spin from IAC. IAC underperformed the Nasdaq and S+P by ~25% from announcement to close of the spin, which could have been exacerbated by the Diller-Malone lawsuit. While these assets are different, as is the investment climate and the ownership dynamics, there is risk that history could repeat itself.

Notablecalls: It appears Barry Diller, Chairman and majority owner of Expedia is back to his old tricks. As many of you probably remember, Expedia is actually a spin off of IACI, which is chaired by none else than Diller himself.

I see a 3 reasons to keep EXPE on the radar this morning:

- While most of the analyst community sees the break-up news as a mild positive for the stock, there are no upgrades or notable target raises this morning. Even the more bullish Tripadvisor valuation scenarios only reach $28-30 for the current combined entity.

- The stock has been acting heavy even in light of positive news. I highlighted a rather major upgrade from Citigroup on March 8 but the stock failed to produce a meaningful move.

On Monday the company announced a favourable settlement with AMR (NYSE:AMR). The stock gapped up +1pt the following morning but only to give up the gain over the next couple of days.

- I like the fact the RBC analyst making the fade call is actually a l-t bull in the name. That I think lends some credibility to the call. I also like his IACI comparison.

The stock is likely to open in the $25-26 range (where it traded in after hours) & I think watching for topping action and fading the strength may be the way to go here.

On the other hand, shorting the name may be such an obvious trade it ends up trapping everyone causing the stock to squeeze eventually. Several million shares were bought last night. These guys are either super smart or super trapped. So adjust your risk accordingly.

Feedback appreciated.

Read more at Notable Calls



Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Lion’s Mane Mushroom

Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes:

Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.

Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.

Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.

Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.

Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.

Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules. Today Be 100% Satisfied Or Receive A Full Money Back Guarantee Order Yours Today By Following This Link.

Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.